Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...

ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, ...

GeoVax’s MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19), primarily targeted to address the current unmet needs inducing broad T-cell and antibody ...

GeoVax Labs Inc. reported its financial results for the first quarter of 2025, showing revenues of 1.6 million dollars, primarily derived from a BARDA contract. The company experienced a net loss ...

--GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a ...

GeoVax has other ongoing Phase 2 trials assessing GEO-CM04S1 as a primary vaccine for immunocompromised patients and as a durable booster for individuals previously vaccinated with mRNA vaccines.

If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at [email protected]. GeoVax Labs, Inc. is a ...